Posted by Michael Wonder on 26 Aug 2019
Drug-price reforms need not affect research on rare diseases – or the Canadians who have them
26 August 2019 - On 9 August, the Patented Medicine Prices Review Board of Canada announced new drug-pricing regulations for new patented medicines that will go into effect in 2020.
And that has raised worries among those with rare diseases, as well as their advocates.
Some patients and advocacy groups are concerned that these changes will greatly disadvantage access of Canadian children and adults with rare and ultra-rare genetic disorders to new effective treatments.
